Remdesivir is an IV administered antiviral and one of the first agents to show a benefit by reducing the time to clinical recovery in COVID-19.50 Remdesivir is a minor substrate for several metabolic and transport pathways, including plasma and tissue esterases, CYP enzymes (CYP3A4, CYP2D6, and CYP2C8), and transporters (OATP1B1 and P-gp). Here, PGP is linked to COVID-19.